CRD initially partnered with Form Bio to improve a DMD therapeutic candidate that was not yet optimized for manufacturing or reduced immunogenicity. Using long-read sequencing, genome integrity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback